申请人:MOLECULAR DEFENSES CORP
公开号:WO2017091737A1
公开(公告)日:2017-06-01
Disclosed herein is glutathione in conjunction with an isoselenazol or isothiazol derivative, e.g., ebselen or ebsulfur derivative, to treat diabetes, lupus, or other chronic inflammatory disease. The glutathione is preferably provided in a rapid release oral formulation that presents the glutathione for absorption in the first part of the ileum. The isoselenazol or isothiazol derivative is preferably provided in a delayed release formulation to avoid overlapping high enteric concentration. These may be provided within the same unit dosage form.
本文披露了谷胱甘肽与异硒唑或异硫唑衍生物(例如ebselen或ebsulfur衍生物)结合治疗糖尿病、狼疮或其他慢性炎症性疾病的方法。谷胱甘肽最好以快速释放口服制剂的形式提供,以便在回肠的第一部分中吸收谷胱甘肽。异硒唑或异硫唑衍生物最好以延迟释放制剂的形式提供,以避免重叠的高肠内浓度。这些可以在同一单位剂量形式中提供。